Fabian Lang
About
Fabian Lang is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Fabian Lang has authored 39 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Genetics and 12 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Fabian Lang's work include Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Acute Lymphoblastic Leukemia research (12 papers). Fabian Lang is often cited by papers focused on Chronic Myeloid Leukemia Treatments (28 papers), Chronic Lymphocytic Leukemia Research (22 papers) and Acute Lymphoblastic Leukemia research (12 papers). Fabian Lang collaborates with scholars based in Germany, United States and Australia. Fabian Lang's co-authors include Jörge E. Cortes, Roman Pfeifer, Andreas Hochhaus, Timothy P. Hughes, Delphine Réa, Gesine Bug, Oliver G. Ottmann, Massimo Breccia, Michael J. Mauro and Hubert Serve and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Heart Journal.
In The Last Decade
Fabian Lang
32 papers receiving 284 citations
Peers
Fabian Lang
Nataliia Glushko Ukraine
Jeffrey Skinner United States
Lauren T. Adrian United States
Katy Knight United Kingdom
Uwe Schwindel Germany
Véronique Bédoucha Switzerland
Arta Dreimane Sweden
Cristina Bucelli Italy
Soo-Young Choi South Korea
Juan Julio Kassack Ipiña Mexico
Citations per year, relative to Fabian Lang Fabian Lang (= 1×)
peers
Nataliia Glushko
Countries citing papers authored by Fabian Lang
Since
Specialization
Citations
This map shows the geographic impact of Fabian Lang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabian Lang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabian Lang more than expected).
Fields of papers citing papers by Fabian Lang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Fabian Lang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabian Lang. The network helps show where Fabian Lang may publish in the future.
Co-authorship network of co-authors of Fabian Lang
This figure shows the co-authorship network connecting the top 25 collaborators of Fabian Lang. A scholar is included among the top collaborators of Fabian Lang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabian Lang. Fabian Lang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cortes, Jörge E., Fabian Lang, Delphine Réa, et al.. (2025). Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia. 39(5). 1124–1134.
2.
Lang, Fabian, Andreas Voß, Guido Kobbe, et al.. (2025). Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leukemia & lymphoma. 66(6). 1079–1087.
3.
Lang, Fabian, Delphine Réa, Naoto Takahashi, et al.. (2025). Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey. Haematologica. 111(2). 597–608.
4.
Lang, Fabian, Björn Steffen, Thomas Oellerich, et al.. (2024). Central nervous system relapse after allogeneic HCT in FLT3-mutated AML. Annals of Hematology. 103(12). 5387–5393.
5.
Ernst, Thomas, Jenny Rinke, Philipp le Coutre, et al.. (2024). The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients. Blood. 144(Supplement 1). 1774–1774.
6.
Pfeifer, Roman, Fabian Lang, Walter Fiedler, et al.. (2024). Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation. Blood. 144(Supplement 1). 840–840.
7.
Kessel, Johanna, Gesine Bug, Björn Steffen, et al.. (2024). Risk factors and outcome of Pseudomonas aeruginosa bloodstream infections (PABSI) in hematological patients: a single center retrospective cohort study. Infection. 53(4). 1383–1392.
8.
Lang, Fabian, et al.. (2024). Interventional antibiotic treatment replacing antibiotic prophylaxis during allogeneic hematopoietic stem cell transplantation is safe and leads to a reduction of antibiotic administration. Annals of Hematology. 103(11). 4687–4699.
9.
Lang, Fabian, et al.. (2024). Cell-resistant wavelength-shifting molecular beacons made of l -DNA and a clickable l -configured uridine. Organic & Biomolecular Chemistry. 22(22). 4568–4573.
10.
Lang, Fabian, et al.. (2024). N-acetyl-beta-D-glucosaminidase and kidney injury molecule 1: detection of potential tubular injury in atrial fibrillation. European Heart Journal. 45(Supplement_1).
11.
Cremer, Anjali, Julius C. Enßle, Fabian Lang, et al.. (2023). Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML. Annals of Hematology. 102(10). 2903–2908.
12.
Fischer, D, et al.. (2023). Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome–negative acute lymphoblastic leukemia. Annals of Hematology. 103(2). 489–498.
13.
Lang, Fabian, Susan Branford, Joseph P. Lyssikatos, Helen Collins, & Andreas Hochhaus. (2023). P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES. HemaSphere. 7(S3). e32603d4–e32603d4.
14.
Pfeifer, Roman, Fabian Lang, Walter Fiedler, et al.. (2023). P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13. HemaSphere. 7(S3). e33834d6–e33834d6.
15.
Cortes, Jörge E. & Fabian Lang. (2021). Third-line therapy for chronic myeloid leukemia: current status and future directions. Journal of Hematology & Oncology. 14(1). 44–44.
16.
Lang, Fabian, Lydia Wunderle, Eberhard Schleyer, et al.. (2020). A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. BMC Pharmacology and Toxicology. 21(1). 70–70.
17.
Cortes, Jörge E., Timothy P. Hughes, Michael J. Mauro, et al.. (2020). Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Blood. 136(Supplement 1). 47–50.
18.
Saußele, Susanne, Wilhelm Haverkamp, Fabian Lang, et al.. (2019). Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Leukemia: Recommendations of a German Expert Consensus Panel with Focus on Cardiovascular Management. Acta Haematologica. 143(3). 217–231.
19.
Pfeifer, Roman, Stéphanie Fey, Julia Obländer, et al.. (2013). In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission. Blood. 122(21). 231–231.
20.
Krieger, O., H. Kasparu, Michael Girschikofsky, et al.. (1997). 181 Cladribine (2-CDA) is active in “high-risk”-chronic myelomonocytic leukemia and secondary or relapsed acute myelo(Mono)cytic leukemia. Leukemia Research. 21(1). S48–S48.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nataliia Glushko Breakdown of academic impact, for papers by Jeffrey Skinner Breakdown of academic impact, for papers by Lauren T. Adrian Breakdown of academic impact, for papers by Katy Knight Breakdown of academic impact, for papers by Uwe Schwindel Breakdown of academic impact, for papers by Véronique Bédoucha Breakdown of academic impact, for papers by Arta Dreimane Breakdown of academic impact, for papers by Cristina Bucelli Breakdown of academic impact, for papers by Soo-Young Choi Breakdown of academic impact, for papers by Juan Julio Kassack Ipiña